Previously active trials

All Types of Amyloid

None currently

Systemic Light Chain Amyloidosis (AL) trials

  • A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis. The first part of the study is phase 1 dose-escalation and the second part will be phase 2.
  • An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2(Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, Bcl-2 inhibitor ZN-d5 targets, binds to and inhibits the activity of Bcl-2.

  • A Phase 3 Randomized, MultI-Centre Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs Placebo Plus Standard of Care in Newly Diagnosed Mayo Stage IV Subjects with Light Chain AL Amyloidosis
  • Birtamimab is a humanized monoclonal antibody being investigated as a treatment for amyloid light chain (AL) amyloidosis and potentially AA amyloidosis.

Transthyretin Amyloidosis (ATTR) trials

  • This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02.
  • AT-02 is a therapeutic candidate developed by Attralus for treating systemic amyloidosis. It’s a fusion protein consisting of a pan-amyloid removal (PAR) peptide technology and a humanized IgG1 antibody. The PAR peptide binds to all types of amyloid and delivers the antibody to the amyloid deposits, stimulating the immune system to remove the amyloid.

  • A phase 1, randomized, placebo-controlled, double-blind, dose escalation trial combining single-ascending dose and multiple-ascending dose phases of NI006 or placebo, followed by an open-label extension phase in subjects with Amyloid Transthyretin Cardiomyopathy (ATTR-CM).
  • NI006 is a recombinant human anti-ATTR antibodythat was developed for the removal of ATTR by phagocytic immune cells.